247 terminated. 247 Phase 2, 83 Phase 1, 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 247 | Terminated 247 |
| Phase 1 | 83 | Terminated 83 |
| Phase 3 | 4 | Terminated 4 |
Follow Multiple Myeloma: new trials by email Literature Review of Multiple Myeloma trials Research Report on Multiple Myeloma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma Forimtamig, Carfilzomib, Daratumumab - Relapsed or Refractory Multiple Myeloma | Phase 1 / Phase 2 | Terminated | Hoffmann-La Roche | 21 | 2023-12-08 | 2026-09-29 |
| A Study of Modakafusp Alfa Together With Daratumumab Adults With Relapsed or Refractory Multiple Myeloma Modakafusp Alfa, Daratumumab - Multiple Myeloma | Phase 1 / Phase 2 | Terminated | Teva Branded Pharmaceutical Products R&D LLC | 15 | 2023-01-23 | 2026-01-30 |
| Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma ISB 1442 SC injection escalating doses, ISB 1442 SC injection at RP2D - Relapsed/Refractory Multiple Myeloma | Phase 1 / Phase 2 | Terminated | Ichnos Sciences SA | 29 | 2022-09-27 | 2025-01-17 |
| Maintenance Belantamab Mafodotin (Blenrep®) After B-cell Maturation Antigen-Directed Chimeric Antigen Receptor T-cell Therapy in Patients With Relapsed and/or Refractory Multiple Myeloma Belantamab mafodotin - Refractory Multiple Myeloma, Relapse Multiple Myeloma | Phase 2 | Terminated | Medical College of Wisconsin | 1 | 2022-07-19 | 2025-01-28 |
| Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma Bone Marrow Biopsy, Dexamethasone, Lenalidomide - Multiple Myeloma, Recurrent Multiple Myeloma | Phase 2 | Terminated | Mayo Clinic | 17 | 2022-06-15 | 2026-09-28 |
| Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies Pembrolizumab - Multiple Myeloma, Multiple Myeloma in Relapse | Phase 2 | Terminated | Alfred Chung, MD | 3 | 2022-05-03 | 2025-01-15 |
| A Study of Daratumumab With Pomalidomide, Dexamethasone, and All-Transretinoic Acid in Patients With Multiple Myeloma Daratumumab, Pomalidomide, All-trans retinoic acid - Multiple Myeloma | Phase 2 | Terminated | Hackensack Meridian Health | 1 | 2022-05-02 | 2025-02-25 |
| PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma PHE885 - Multiple Myeloma | Phase 2 | Terminated | Novartis Pharmaceuticals | 146 | 2022-03-03 | 2026-01-13 |
| Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma Patients Selinexor, Clarithromycin, Pomalidomide - Myeloma Multiple, Myeloma | Phase 2 | Terminated | Weill Medical College of Cornell University | 4 | 2021-12-29 | 2023-10-25 |
| Belantamab Mafodotin, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma Belantamab Mafodotin, Cyclophosphamide and Dexamethasone - Relapsed/Refractory Multiple Myeloma | Phase 1 / Phase 2 | Terminated | University of Maryland, Baltimore | 10 | 2021-12-03 | 2025-04-03 |
| Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy Descartes 08 - Myeloma Multiple | Phase 2 | Terminated | Cartesian Therapeutics | 13 | 2021-12-01 | 2024-10-08 |
| Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma Magrolimab, Daratumumab, Pomalidomide - Multiple Myeloma | Phase 2 | Terminated | Gilead Sciences | 36 | 2021-11-09 | 2025-05-02 |
| MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma Elranatamab + Nirogacestat, Elranatamab + lenalidomide + dexamethasone - Multiple Myeloma | Phase 2 | Terminated | Pfizer | 46 | 2021-10-27 | 2026-04-24 |
| To Assess the Safety and Tolerability of INCB000928 in Participants With Myelodysplastic Syndromes or Multiple Myeloma INCB000928 - Myelodysplastic Syndromes, Multiple Myeloma | Phase 1 / Phase 2 | Terminated | Incyte Corporation | 22 | 2021-08-19 | 2025-10-22 |
| Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma ALLO-605, ALLO-647, Fludarabine - Relapsed/Refractory Multiple Myeloma | Phase 1 / Phase 2 | Terminated | Allogene Therapeutics | 6 | 2021-06-06 | 2024-06-28 |
| A Ph1/2 Study of EMB-06 in Participants With Relapsed or Refractory Myeloma EMB-06 - Relapsed or Refractory Multiple Myeloma | Phase 1 / Phase 2 | Terminated | Shanghai EpimAb Biotherapeutics Co., Ltd. | 40 | 2021-05-20 | 2025-05-28 |
| GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies GEN3014, Daratumumab - Relapsed or Refractory Multiple Myeloma (RRMM), Diffuse Large B Cell Lymphoma (DLBCL) | Phase 1 / Phase 2 | Terminated | Genmab | 130 | 2021-03-09 | 2026-05-19 |
| Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Dostarlimab (GSK4057190) in Participants With RRMM Belantamab Mafodotin, Dostarlimab - Relapsed/Refractory Multiple Myeloma | Phase 1 / Phase 2 | Terminated | GlaxoSmithKline | 4 | 2021-03-09 | 2025-03-03 |
| Xisomab 3G3 for the Prevention of Catheter-Associated Thrombosis in Patients With Cancer Receiving Chemotherapy Xisomab 3G3 - Lymphoma, Malignant Solid Neoplasm | Phase 2 | Terminated | OHSU Knight Cancer Institute | 9 | 2021-02-25 | 2024-01-24 |
| Safety and Efficacy Study of OPC-415 in Patients With Relapsed and/or Refractory Multiple Myeloma OPC-415 - Multiple Myeloma (MM) | Phase 1 / Phase 2 | Terminated | Otsuka Pharmaceutical Co., Ltd. | 11 | 2021-02-18 | 2026-09-14 |
Showing 20 of 247. Sign in to see all of them.
Neoplasms, Plasma Cell (42) · Recurrence (35) · Lymphoma (34) · Myelodysplastic Syndromes (34) · Leukemia (29) · Hodgkin Disease (27) · Lymphoma, Non-Hodgkin (25) · Leukemia, Lymphocytic, Chronic, B-Cell (22) · Leukemia, Myeloid, Acute (22) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (19) · Myeloproliferative Disorders (18) · Lymphoma, Mantle-Cell (17) · Lymphoma, Large B-Cell, Diffuse (15) · Primary Myelofibrosis (14)
Cardiovascular Diseases (247) · Hemic and Lymphatic Diseases (247) · Hemorrhagic Disorders (247) · Hemostatic Disorders (247) · Immune System Diseases (247) · Immunoproliferative Disorders (247) · Vascular Diseases (247) · Blood Protein Disorders (246) · Neoplasms by Histologic Type (246) · Paraproteinemias (245) · Hematologic Diseases (244) · Lymphoproliferative Disorders (243) · Neoplasms (236) · Neoplasms, Plasma Cell (205) · Lymphatic Diseases (56)
Dexamethasone (71) · Bortezomib (42) · Calcium Dobesilate (31) · Cyclophosphamide (27) · Lenalidomide (27) · Melphalan (23) · pomalidomide (19) · Filgrastim (16) · carfilzomib (15) · fludarabine phosphate (14) · Antilymphocyte Serum (12) · Tacrolimus (12) · daratumumab (12) · fludarabine (11) · Granulocyte Colony-Stimulating Factor (10)
National Cancer Institute (NCI) (12) · Masonic Cancer Center, University of Minnesota (9) · Incyte Corporation (6) · NYU Langone Health (6) · H. Lee Moffitt Cancer Center and Research Institute (5) · Hackensack Meridian Health (5) · M.D. Anderson Cancer Center (5) · Oncotherapeutics (5) · Washington University School of Medicine (5) · Amgen (4) · Celgene (4) · Gilead Sciences (4) · Mayo Clinic (4) · University of Arkansas (4) · Weill Medical College of Cornell University (4)
United States (206) · France (16) · Spain (16) · Canada (15) · Italy (13) · Australia (11) · Germany (11) · United Kingdom (9) · Denmark (8) · Czechia (7) · Greece (7) · South Korea (7) · Belgium (6) · China (5) · Japan (5)
James R Berenson, MD (4) · Amitabha Mazumder, MD (3) · Maurizio Zangari, MD (3) · Ravi Vij, M.D. (3) · Alfred Chung, MD (2) · Alfred Garfall, MD (2) · Fabio Ciceri, MD (2) · Fred Zheng, M.D. (2) · Melissa Alsina, M.D. (2)
PMID 31527168, PMID 17579184, PMID 19179301, PMID 20067838, PMID 21403127, PMID 21874061, PMID 22080968, PMID 22430088, PMID 23205612, PMID 23426943, PMID 24241210, PMID 24658821, PMID 26384354, PMID 28140719, PMID 28461396, PMID 29141948, PMID 29567784, PMID 30123673, PMID 30190454, PMID 30230047, PMID 31215818, PMID 31229804, PMID 31443741, PMID 33357481, PMID 33554732, PMID 34551886, PMID 34818965, PMID 34951522, PMID 35176457, PMID 36269898, PMID 36460794, PMID 36639200, PMID 37290996, PMID 37399355, PMID 37646702, PMID 37970718, PMID 38517235, PMID 39187595, PMID 39540213, PMID 39630057, PMID 40279508, PMID 40485906, PMID 41041907, PMID 41043099, PMID 42097596
2018 (4), 2017 (3), P30CA016058 (3), 2008 (2), 2016 (2), 2019 (2), 2023 (2), P30CA015083 (2), P30CA015704 (2), P30CA022453 (2), U10CA032102 (2), 2014 (1), N01CM00070 (1), N01CM62203 (1), N01CM62204 (1)